COLUMBIA, S.C., October 12, 2020 – Developers of SinuSonic, a first of its kind medical device for natural relief of nasal congestion using acoustic humming and oscillating pressure, are seeking applicants for a new independent medical study in coordination with researchers at the Medical University of South Carolina. The study will aid researchers in determining the efficacy of SinuSonic for preventing viral upper respiratory infections.
Upper respiratory infections are commonly caused by viruses such as influenza, rhinovirus, and coronaviruses. “Nitric oxide has been shown to have anti-viral and anti-bacterial properties and stimulate muco-ciliary clearance, leading to improved congestion and the potential relief of other related symptoms. Our prior research has shown that acoustic vibrations trigger an increase in nitric oxide release from the sinuses and nasal passages,” said Dr. Rodney Schlosser, Director of Rhinology and Sinus Surgery at the Medical University of South Carolina (MUSC) and co-Medical Director at SinuSonic. “We are eager to see whether regular use of SinuSonic during cold and flu season can decrease the chance of getting sick from one of these viruses.”
Medical studies unrelated to SinuSonic are already researching the positive effects of externally administering nitric oxide as a potential treatment for upper respiratory infections, including COVID-19. This latest SinuSonic independent study will take the theory a step further by measuring the body’s ability to prevent infection through harnessing its own natural production of nitric oxide spurred by using the SinuSonic device. Originally developed to treat chronic nasal congestion without drugs or mess, SinuSonic offers patients the ability to treat moderate to severe nasal congestion by simply breathing into a device, triggering the application of gentle acoustic vibrations and light resistant pressure to provide natural relief.
“A simple and inexpensive way of reducing viral respiratory infections would have tremendous impact for millions of Americans” stated Dr. Zachary Soler, Associate Professor in the Division of Rhinology, also at the Medical University of South Carolina and co-Medical Director of SinuSonic. “Since its inception, SinuSonic has been committed to scientific inquiry. We are eager to bring participants on board into this real-world clinical trial.”
Results from an independent study published in the February 2020 edition of the International Forum of Allergy and Rhinology found more than 80 percent of trial subjects experienced clinically and statistically significant improvements in self-reported nasal congestion scores. Additionally, the SinuSonic device was found to be safe and well tolerated and improves objective AND subjective outcomes in chronic rhinitis. In fact, 87.5% of subjects would recommend SinuSonic to a friend or family member.
To participate in the study, applicants should email Matthew Germroth at email@example.com